Cashmere production from Scottish Cashmere kids and crossbreed Scottish Cashmere x Jonica kids

This study is part of a much wider research programme to evaluate the possibility of producing valuable textile fibres, such as cashmere, from goat breeds reared in Italy. In order to achieve this, we have used crossbreeding. The first stage of the programme consisted of evaluating cashmere production in F1 kids obtained by crossing white-haired Jonica does, which have no secondary fibres, with Scottish Cashmere bucks. The trial lasted one year starting in March 2007, and took place in the Department of Animal Production of the University of Bari (Italy). We used 14 male kids: 7 Scottish Cashmere (SC group), and 7 F1 (SC x J group) derived from crossing Scottish Cashmere bucks with does of the Jonica breed, commonly reared in southern Italy. All the parameters considered (live weight, number and active percentage of primary and secondary follicles, S/P ratio, patch weight, growth and length of guard hair and down, yield, down production and diameter, blood protein and T3 and T4) were significantly influenced (P<0.01) by age. Genotype also had a significant effect (P<0.01) on all parameters except for the active percentage of primary follicles and the blood protein level. The factors which influence down production showed the heterosis effect to a varying extent in F1, but they still produced significantly less than the SC group kids (38.5±4.04 vs 68.5±9.16 g; P<0.01). These results are largely due to both their low number of secondary follicles (30.0±1.46 vs 39.3±1.02; P<0.01), which also have a lower percentage of activity (64.7±2.47 vs 90.0±1.53; P<0.01), and also to the down length which was 28% shorter than in SC group. This genetic combination is clearly unsatisfactory so others must be sought, probably by using more rustic local breeds, as well as more productive breeds for crossbreeding

Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial

Rationale: Pulse glucocorticoid therapy is used in hyperinflammation related to coronavirus 2019 (COVID-19). We evaluated the efficacy and safety of pulse intravenous methylprednisolone in addition to standard treatment in COVID-19 pneumonia. Methods: In this multicenter, randomised, double-blind, placebo-controlled trial, 304 hospitalised patients with Covid-19 pneumonia were randomised to receive 1 g of methylprednisolone intravenously for 3 consecutive days or placebo in addition to standard dexamethasone. The primary outcome was the duration of the patient hospitalisation, calculated as the time interval between randomisation and hospital discharge without the need of supplementary oxygen. The key secondary outcomes were survival free from invasive ventilation with orotracheal intubation and overall survival. Results: Overall, 112 of 151 (75.4%) patients in the pulse methylprednisolone arm and 111 of 150 (75.2%) in the placebo arm were discharged from hospital without oxygen within 30 days from randomisation. Median time to discharge was similar in both groups [15 days (95% confidence interval (CI), 13.0 to 17.0) and 16 days (95%CI, 13.8 to 18.2); hazard ratio (HR), 0.92; 95% CI 0.71-1.20; p=0.528]. No significant differences between pulse methylprednisolone and placebo arms were observed in terms of admission to Intensive Care Unit with orotracheal intubation or death (20.0% versus 16.1%; HR, 1.26; 95%CI, 0.74-2.16; p=0.176), or overall mortality (10.0% versus 12.2%; HR, 0.83; 95%CI, 0.42-1.64; p=0.584). Serious adverse events occurred with similar frequency in the two groups. Conclusions: Methylprenisolone pulse therapy added to dexamethasone was not of benefit in patients with COVID-19 pneumonia. Message of the study: Pulse glucocorticoid therapy is used for severe and/or life threatening immuno-inflammatory diseases. The addition of pulse glucocorticoid therapy to the standard low dose of dexamethasone scheme was not of benefit in patients with COVID-19 pneumonia

The impact of chest CT body composition parameters on clinical outcomes in COVID-19 patients

We assessed the impact of chest CT body composition parameters on outcomes and disease severity at hospital presentation of COVID-19 patients, focusing also on the possible mediation of body composition in the relationship between age and death in these patients. Chest CT scans performed at hospital presentation by consecutive COVID-19 patients (02/27/2020-03/13/2020) were retrospectively reviewed to obtain pectoralis muscle density and total, visceral, and intermuscular adipose tissue areas (TAT, VAT, IMAT) at the level of T7-T8 vertebrae. Primary outcomes were: hospitalization, mechanical ventilation (MV) and/or death, death alone. Secondary outcomes were: C-reactive protein (CRP), oxygen saturation (SO2), CT disease extension at hospital presentation. The mediation of body composition in the effect of age on death was explored. Of the 318 patients included in the study (median age 65.7 years, females 37.7%), 205 (64.5%) were hospitalized, 68 (21.4%) needed MV, and 58 (18.2%) died. Increased muscle density was a protective factor while increased TAT, VAT, and IMAT were risk factors for hospitalization and MV/death. All these parameters except TAT had borderline effects on death alone. All parameters were associated with SO2 and extension of lung parenchymal involvement at CT; VAT was associated with CRP. Approximately 3% of the effect of age on death was mediated by decreased muscle density. In conclusion, low muscle quality and ectopic fat accumulation were associated with COVID-19 outcomes, VAT was associated with baseline inflammation. Low muscle quality partly mediated the effect of age on mortality.We assessed the impact of chest CT body composition parameters on outcomes and disease severity at hospital presentation of COVID-19 patients, focusing also on the possible mediation of body composition in the relationship between age and death in these patients. Chest CT scans performed at hospital presentation by consecutive COVID-19 patients (02/ 27/2020-03/13/2020) were retrospectively reviewed to obtain pectoralis muscle density and total, visceral, and intermuscular adipose tissue areas (TAT, VAT, IMAT) at the level of T7-T8 vertebrae. Primary outcomes were: hospitalization, mechanical ventilation (MV) and/or death, death alone. Secondary outcomes were: C-reactive protein (CRP), oxygen saturation (SO2), CT disease extension at hospital presentation. The mediation of body composition in the effect of age on death was explored. Of the 318 patients included in the study (median age 65.7 years, females 37.7%), 205 (64.5%) were hospitalized, 68 (21.4%) needed MV, and 58 (18.2%) died. Increased muscle density was a protective factor while increased TAT, VAT, and IMAT were risk factors for hospitalization and MV/death. All these parameters except TAT had borderline effects on death alone. All parameters were associated with SO2 and extension of lung parenchymal involvement at CT; VAT was associated with CRP. Approximately 3% of the effect of age on death was mediated by decreased muscle density. In conclusion, low muscle quality and ectopic fat accumulation were associated with COVID-19 outcomes, VAT was associated with baseline inflammation. Low muscle quality partly mediated the effect of age on mortality

Effect of type of suckling and polyunsaturated fatty acid use on lamb production. 1. Productive performances and quanti-qualitative characteristics of the carcass

The aim of the study was to estimate the influence of artificial rearing and of the addition of polyunsaturated fatty acids(PUFA) to an acidified milk replacer on the productive performances and on the quanti-qualitative characteristics of thecarcass. Fifty one twin-born Gentile di Puglia lambs were subdivided into three homogenous groups (9 females and 8males) assigned the following feeding treatments: maternal milk (MM); acidified milk replacer (MR); acidified milk replacer+ 10 ml/l of a mixture of linseed and fish oil rich in PUFA (MR+PUFA).Milk consumptions and live weights were recorded weekly. Seven males from each group were slaughtered at 45 days ofage and the net warm dressing percentage, the composition of the carcass and the colorimetric characteristics of theLongissimus lumborum muscle were estimated. Artificial rearing improved the daily weight gain (0.182-0.172 vs 0.128Kg; PThe addition of omega-3 fatty acids to the diet did not influence the weight gain, the feed conversion index, the net warmdressing percentage and the incidence of the different meat cuts of the half carcass. However, it significantly increasedthe half carcass length (37.86 vs 35.0 cm; Pto the MR group reduced the proportion of lean (63.21 vs 53.98 %; PP<0.01) in the lumbar region

Dietary supplementation with oregano and linseed in garganica suckling kids: Effects on growth performances and meat quality

Meat from Garganica kids fed diets containing oregano and linseed was analysed for physical and sensory properties, chemical and fatty acid composition of intramuscular lipids. Twenty-one three-week-old kids were divided into three homogeneous groups (n = 7), according to age and body weight, and assigned to one of the following feeding treatments: C) control: commercial pelleted feed; L) pelleted feed containing 3% extruded linseed; LO) pelleted feed containing 3% extruded linseed and 0.6% dried oregano inflorescences. Kids were slaughtered at 60 days of age. Diet did not affect in vivo performances, dressing percentage, pH and meat colour, but it influenced meat tenderness, that was lower (P<0.01) in meat from kids receiving oregano, probably due to the lesser (P<0.05) fat content of their meat. The use of oregano also resulted in a lower muscle fat oxidation and in a better meat flavour. As for human health, the dietary supplementation with linseed improved the muscle fatty acid composition, resulting in higher levels of α-linolenic acid (P<0.05) and in a lower n-6/n-3 ratio

Use of alternative protein sources for finishing lambs. 2. Effects on chemical and physical characteristics and fatty acid composition of meat.

This study investigated the use of different protein sources (soybean, faba bean, sweet lupin and pea) in lamb feed and their influence on the chemical and physical characteristics of the meat and on the acid composition of intramuscular fat. The meat of lambs fed on faba bean contained a greater percentage of fat than those fed on lupin (P < 0.05) and soybean (P < 0.01). The meat of lambs fed on faba bean had a greater (P < 0.01) proportion of PUFA and a higher PUFA/SFA ratio than the meat of all other groups. The thrombogenicity index and nutritive value of meat fat were higher for lambs fed with faba bean and pea. The use of lupin in feed determined the highest (P < 0.01) SFA percentage, the lowest PUFA incidence and the worst thrombogenicity index. In conclusion, the protein sources studied did not influence the physical characteristics of the meat. However, the acid composition improved with the use of pea, and especially of faba bean

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

BackgroundTocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.MethodsA multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.ResultsIn the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6-24.0, P=0.52) and 22.4% (97.5% CI: 17.2-28.3, P&lt;0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.ConclusionsTocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

BackgroundTocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.MethodsA multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.ResultsIn the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6-24.0, P=0.52) and 22.4% (97.5% CI: 17.2-28.3, P&lt;0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.ConclusionsTocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)